Glycemic Control with Apidra®
The Flexibility to be used in both type 1 and type 2
adult diabetes patients
Apidra® provides effective glycemic control
for type 2 diabetes patients
Comparable reductions in A1C vs RHI in type 2 diabetes patients (mean BMI=34.55)2,10
Mean change in A1C(%) from baseline* (N=876)2,10
A 26-week, randomized, open-label, active-control study compared Apidra
® with RHI given premeal (both groups were given intermediate-acting basal insulin twice daily; mean baseline A1C <7.6%).
² "Endpoint" was the last available measurement after start of treatment.
¹ Apidra
® or RHI was individually dosed as appropriate prior to at least 2 meals a day (breakfast and dinner).
¹ The mean number of daily short-acting insulininjections at endpoint was 2.27 for Apidra
® (n=404) and 2.24 for RHI (n=403).
² The mean BMI was 34.55 kg/m².
*The baseline A1C value was 7.57% for Apidra
® and 7.50% for RHI.
²
- Reductions from baseline were similar between both treatment groups2
- The clinical relevance of the differences in A1C reduction between RHI and Apidra® is unknown
- Efficacy was maintained regardless of presence or absence of oral hypoglycemic agent use10
Postprandial control achieved with both Apidra® and RHI in type 2 diabetes patients
- Significantly lower mean blood glucose levels from baseline at 2 hours postbreakfast and 2 hours postdinner10
- Apidra ® and RHI provided consistently low premeal blood glucose levels10
Apidra® provides effective glycemic control for type 1 diabetes patients
Equal reductions in A1C vs lispro in type 1 diabetes patients(mean BMI=24.99)1,2
IMPORTANT SAFETY INFORMATION FOR APIDRA®
Apidra® is a rapid-acting human insulin analog indicated to improve
glycemic control in adults with type 2 diabetes or adults and children (4 years
and older) with type 1 diabetes. Apidra® is contraindicated during
episodes of hypoglycemia and in patients hypersensitive to Apidra®
or any of its excipients. Apidra® should normally be used in regimens
that include a longer-acting insulin.
OptiClik® is a reusable insulin delivery device for use with a 3-mL
Apidra® cartridge (U-100).
Needles, OptiClik® and cartridge systems must not be shared.
Apidra® has a more rapid onset and shorter duration of action than
regular human insulin. When used as a mealtime insulin, the dose of Apidra®
should be given within 15 minutes before or within 20 minutes after starting a meal.
Glucose monitoring is essential for patients receiving insulin therapy. Any change
in insulin and/or regimen should be made cautiously, only under medical supervision,
and may require a change in dose. Concomitant oral antidiabetic treatment may need
to be adjusted. As with all insulin preparations, the time course of Apidra®
action may vary by individual or at different times in the same individual and depends
on injection site, blood supply, temperature, and level of physical activity.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®.
The timing of hypoglycemia usually reflects the time-action profile of the administered
insulin formulations. Other adverse events associated with Apidra®
include hypokalemia, allergic reactions, injection site reactions, lipodystrophy,
pruritus, and rash. Less common, but potentially more serious or life-threatening,
is generalized allergy to insulin, including anaphylactic reactions.
Apidra® should not be
mixed with other insulins or with a diluent when used in the pump.
Please click here for full prescribing information for Apidra®
